Others
- Page Path
-
- HOME
- ARTICLE CATEGORY
- Others
- Reply to Correspondence
- Decreasing systemic inflammation after TIPS: Still hope for the liver: Reply to correspondence on “Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis”
- Georg Semmler, Lorenz Balcar, Mattias Mandorfer
- Clin Mol Hepatol. 2025;31(2):e224-e225. Published online February 17, 2025
-
View: 916 Download: 37
- Correspondence
- The burden of steatotic liver disease before and during the COVID-19 pandemic: Correspondence to editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023”
- Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed
- Clin Mol Hepatol. 2025;31(2):e183-e185. Published online February 17, 2025
-
View: 897 Download: 16 Crossref: 1
- Correspondence to editorial on “Exploring methylation signatures for high de novo recurrence risk in hepatocellular carcinoma”
- Kwang-Woong Lee, Young-Joon Kim
- Clin Mol Hepatol. 2025;31(2):e206-e207. Published online February 17, 2025
-
View: 853 Download: 25
- Correspondence to editorial on “Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000-2021”
- Pojsakorn Danpanichkul, Luis Antonio Diaz, Kanokphong Suparan, Karn Wijarnpreecha, Juan Pablo Arab
- Clin Mol Hepatol. 2025;31(2):e200-e202. Published online February 17, 2025
-
View: 1372 Download: 32
- Correspondence to editorial on “Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C”
- Tom Ryu, Young Chang, Seung Up Kim, Jae Young Jang
- Clin Mol Hepatol. 2025;31(2):e203-e205. Published online February 24, 2025
-
View: 754 Download: 19 Web of Science: 1 Crossref: 1
- Correspondence to editorial on “Prediction of primary biliary cholangitis among health check-up population with anti-mitochondrial M2 antibody positive”
- Haolong Li, Song Liu, Xu Wang, Li Wang, Tengda Xu, Yongzhe Li
- Clin Mol Hepatol. 2025;31(2):e194-e196. Published online February 24, 2025
-
View: 913 Download: 33
- Correspondence to editorial on “Integrated molecular characterization of sarcomatoid hepatocellular carcinoma”
- Rong-Qi Sun, Shao-Lai Zhou
- Clin Mol Hepatol. 2025;31(2):e192-e193. Published online February 26, 2025
-
View: 819 Download: 22
- Reply to Correspondence
- Reply to correspondence 2 on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”
- Nahee Hwang, Sungsoon Fang
- Clin Mol Hepatol. 2025;31(2):e228-e231. Published online February 26, 2025
-
View: 976 Download: 27
- Reply to correspondence on “Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C”
- Chen-Hua Liu, Yu-Ping Chang
- Clin Mol Hepatol. 2025;31(2):e232-e233. Published online February 26, 2025
-
View: 739 Download: 22
- Reply to correspondence on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023”
- Jeayeon Park, Su Jong Yu
- Clin Mol Hepatol. 2025;31(2):e221-e223. Published online March 4, 2025
-
View: 735 Download: 8
- Special Issue
- KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025
- Won Sohn, Young-Sun Lee, Soon Sun Kim, Jung Hee Kim, Young-Joo Jin, Gi-Ae Kim, Pil Soo Sung, Jeong-Ju Yoo, Young Chang, Eun Joo Lee, Hye Won Lee, Miyoung Choi, Su Jong Yu, Young Kul Jung, Byoung Kuk Jang, on behalf of The Korean Association for the Study of the Liver (KASL)
- Clin Mol Hepatol. 2025;31(Suppl):S1-S31. Published online February 19, 2025
-
View: 1745 Download: 194 Web of Science: 2 Crossref: 5
- Correspondence
- Correspondence to editorial on “UBE2S promotes glycolysis in hepatocellular carcinoma by enhancing E3 enzyme-independent polyubiquitination of VHL”
- Renyu Zhang, Ding Wei, Zhinan Chen, Huijie Bian
- Clin Mol Hepatol. 2025;31(1):e58-e60. Published online July 29, 2024
-
View: 1175 Download: 58 Web of Science: 1 Crossref: 1
- Reply to Correspondence
- Reply to correspondence on “UBE2S: A novel driver of HIF-1alpha-induced metabolic reprogramming in hepatocellular carcinoma”
- Martina Mang Leng Lei, Terence Kin Wah Lee
- Clin Mol Hepatol. 2025;31(1):e119-e120. Published online August 5, 2024
-
View: 1120 Download: 40
- Correspondence
- Correspondence to letter to the editor on “Non-linear association between liver fibrosis scores and viral load in patients with chronic hepatitis B”
- Gi-Ae Kim, Seung Won Choi, Young-Suk Lim
- Clin Mol Hepatol. 2025;31(1):e108-e109. Published online August 5, 2024
-
View: 1198 Download: 35
- Steatotic liver disease in chronic hepatitis C related hepatocellular carcinoma: Inflictor or bystander?: Correspondence to editorial on “Dynamic change of metabolic dysfunction-associated steatotic liver disease in chronic hepatitis C patients after viral eradication: A nationwide registry study in Taiwan”
- Chung-Feng Huang, Ming-Lun Yeh, Chia-Yen Dai, Jee-Fu Huang, Wan-Long Chuang, Ming-Lung Yu
- Clin Mol Hepatol. 2025;31(1):e64-e66. Published online August 19, 2024
-
View: 1360 Download: 53 Web of Science: 1 Crossref: 1
- PNPLA3 is one of the bridges between TM6SF2 E167K variant and MASLD: Correspondence to editorial on “TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD”
- Baokai Sun, Likun Zhuang
- Clin Mol Hepatol. 2025;31(1):e67-e69. Published online September 10, 2024
-
View: 1268 Download: 83
- Correspondence to editorial on “KCTD17-mediated Ras stabilization promotes hepatocellular carcinoma progression”
- Sang Bae Lee, KyeongJin Kim
- Clin Mol Hepatol. 2025;31(1):e78-e80. Published online September 10, 2024
-
View: 1184 Download: 74
- Correspondence to editorial on “DNA methylome analysis reveals epigenetic alteration of complement genes in advanced metabolic dysfunction-associated steatotic liver disease”
- Amal Magdy, Hee-Jin Kim, Won Kim, Mirang Kim
- Clin Mol Hepatol. 2025;31(1):e70-e73. Published online September 10, 2024
-
View: 1260 Download: 64
- Correspondence to editorial on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis”
- Hee Yeon Kim, Miyoung Choi, Dae Won Jun
- Clin Mol Hepatol. 2025;31(1):e48-e51. Published online September 11, 2024
-
View: 1241 Download: 26
- Correspondence to letter to the editor on “Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis”
- Yuri Cho, Dae Won Jun
- Clin Mol Hepatol. 2025;31(1):e103-e104. Published online September 24, 2024
-
View: 1171 Download: 41
- Correspondence to editorial on “Optimal cutoffs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis”
- Jung Hwan Yu, Seung Up Kim
- Clin Mol Hepatol. 2025;31(1):e52-e54. Published online September 24, 2024
-
View: 1412 Download: 30
- Correspondence to letter to the editor on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”
- Sung Hwan Lee, Sun Young Yim, Ji Hoon Kim, Sunyoung S Lee, Ahmed O Kaseb, Peng Wei, Ju-Seog Lee
- Clin Mol Hepatol. 2025;31(1):e110-e112. Published online October 2, 2024
-
View: 1293 Download: 50
- Correspondence to editorial on “Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: Systematic review and meta-analysis”
- Young-Joo Jin, Seung Up Kim
- Clin Mol Hepatol. 2025;31(1):e55-e57. Published online October 7, 2024
-
View: 1099 Download: 25 Web of Science: 1 Crossref: 1
- Correspondence to editorial 1 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 Trial”
- Sung Hwan Lee, Sun Young Yim, Ji Hoon Kim, Sunyoung S. Lee, Ahmed O. Kaseb, Ju-Seog Lee
- Clin Mol Hepatol. 2025;31(1):e81-e83. Published online October 7, 2024
-
View: 1296 Download: 36 Crossref: 1
- Correspondence to editorial 2 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 trial”
- Sun Young Yim, Sung Hwan Lee, Ji Hoon Kim, Sunyoung S Lee, Ahmed O Kaseb, Ju-Seog Lee
- Clin Mol Hepatol. 2025;31(1):e84-e86. Published online October 7, 2024
-
View: 1249 Download: 34
- Reply to Correspondence
- Reply to correspondence on “Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting”
- Antonio Bertoletti, Anthony T Tan
- Clin Mol Hepatol. 2025;31(1):e113-e116. Published online October 11, 2024
-
View: 1310 Download: 33
- Reply to correspondence on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”
- Hiroaki Kanzaki, Yujin Hoshida
- Clin Mol Hepatol. 2025;31(1):e121-e122. Published online October 11, 2024
-
View: 1157 Download: 40
- Correspondence
- Correspondence to editorial on: “Gut microbiome and metabolome signatures in liver cirrhosis-related complications”
- Satya Priya Sharma, Ki Tae Suk
- Clin Mol Hepatol. 2025;31(1):e74-e77. Published online October 15, 2024
-
View: 1529 Download: 50
- Correspondence to editorial on “Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis”
- Young Eun Chon, Jung Hwan Yu, Seung Up Kim
- Clin Mol Hepatol. 2025;31(1):e61-e63. Published online October 15, 2024
-
View: 1218 Download: 32
- Correspondence to editorial on “Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting”
- Shunda Du, Karin Wisskirchen, Ke Zhang, Ulrike Protzer
- Clin Mol Hepatol. 2025;31(1):e44-e47. Published online October 21, 2024
-
View: 1381 Download: 45 Crossref: 1
-
Clinical and
Molecular
HepatologyPrint ISSN: 2287-2728
Online ISSN: 2287-285X
-
-
Video abstract
-
- Interventions targeting the gut-liver axis: A potential treatment strategy for metabolic dysfunction-associated steatotic liver disease
- Modulation of lymphatic vessels in management of liver disease and complications
- Metabolic dysfunction-associated steatotic liver disease across women’s reproductive lifespan and issues
- Examining the therapeutic landscape of beta-blockers in portal hypertension
- Immunopathogenesis of liver fibrosis in steatotic liver disease
- Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
- Recent updates on pharmacologic therapy in non-alcoholic fatty liver disease
- The role of the hepatic autonomic nervous system
- HBeAg-positive grey-zone patients: Treatment beyond guideline recommendations?
- Systemic therapy in advanced hepatocellular carcinoma
- Epidemiology and updated management for autoimmune liver disease
- Microbiome and metabolomics in alcoholic liver disease
- Personalized medicine in nonalcoholic fatty liver disease
- Acute on chronic liver failure in cirrhosis
- Current status and outcome of liver transplantation in South Korea
- History and future of hepatitis B virus control in South Korea
- Hepatocellular carcinoma statistics in South Korea
Impact Factor16.9First decision
07 Days
Publication after acceptance
04 Days
*Last 12 months
- MOST VIEWED (Last 6 months)
- MOST CITED (2023-2025)
|
|||||||
